AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KJUN 292 min read$ELTP

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001053369 0001053369 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2026

Original reporting
SEC EDGAR 8-K
Published Jun 29, 2026, 8:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ELTP
Neutral
low confidence
Mentioned
$ELTP
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ELTPNeutralLow
01

Why it matters

The main tradable element from the excerpt is the scheduled investor conference call and the fact that the results were filed/issued; however, no specific financial datapoints are included in the scraped body.

02

Market read

Traders can use the June 30 call as a near-term catalyst, but the excerpt provides no numbers to judge earnings/guidance impact.

03

What to watch

The press release (Exhibit 99.1) likely contains the actionable figures; without it, the true novelty and direction cannot be assessed.

Relevance 7/10Novelty 2/10Timing: ahead of the June 30, 2026 11:30 AM EDT conference call

Background

The company filed an 8-K to report year-end results for the fiscal year ended March 31, 2026, and incorporated a press release as Exhibit 99.1.

Company-level read

Ticker impact

$ELTPNeutralLow confidence
Context

Elite Pharmaceuticals filed its year-end FY2026 results via 8-K Item 2.02 and will host a June 30 conference call for updates.

Expected impact

Near-term volatility possible around the June 30 call, but direction is unclear from the provided excerpt.

Evidence & confidence

The excerpt confirms the 8-K/press-release linkage and call timing, but does not include the actual financial figures or guidance changes.

Market effects

Sector

Limited read-across: OTC-listed pharma results filing with no disclosed sector-wide regulatory/product catalyst here.

Regional

Minimal; US microcap/OTC event with no broader regional macro linkage in the excerpt.

Global

None indicated by the provided text.

Counterpoint

What could challenge this read

Because the excerpt lacks the actual financial numbers, traders may overreact to the call logistics rather than fundamentals.

Key entities

  • company
    Elite Pharmaceuticals, Inc.

    OTC-listed registrant filing 8-K Item 2.02 and scheduling a June 30 conference call to discuss FY2026 results.

  • regulatory_filing
    SEC Form 8-K

    Current report used to furnish results of operations and financial condition plus Regulation FD disclosure.

Read at source← All news

Related articles

AUG 13
$ELTPLow

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026

ELITE PHARMACEUTICALS INC /NV/ (ELTP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 ended June 30, 2026 and Provides Conference Call Information Conference Call Scheduled for Friday, August 14, 2026 at 11:30 AM EDT Northvale, NJ – August 13, 2026: Elite P

SEC EDGAR 8-K2 min
OCT 19
$CLFMedAI 8/10

Cleveland-Cliffs Q3 Earnings Call Highlights

Cleveland-Cliffs (CLF) expects to achieve over $1B adjusted EBITDA per quarter in 2027, with full-year EBITDA potentially exceeding $4B. The outlook is driven by contract renewals, pricing momentum, and contributions from Stelco. The company postponed a blast furnace reline to 2028, preserving production capacity. Capital expenditures are projected to exceed $1B in 2027. Stelco has returned to profitability, but faces import pressures.

finance.yahoo.com3 min
OCT 19
$VFSHigh

What VinFast Auto (VFS) Said on Its Q2 Earnings Call

VinFast reported a Q2 gross margin of -62.8%, with adjusted EBITDA at -$1.1B. The company restructured its Vietnam manufacturing, reducing borrowings by $2.9B. It launched new models and maintained market leadership in Vietnam. VinFast aims for 2026 EBITDA break-even, with 300K EV deliveries targeted, 75% in Vietnam.

finance.yahoo.com3 min